… in asymptomatic household contacts of SARS-CoV-2–infected individuals to assess whether
subcutaneous REGEN-COV … mg of each monoclonal antibody) may prevent infection and/or …

… development of symptomatic SARS-CoV-2 infection through … coronavirus 2 (SARS-CoV-2),
was first detected in December … of subcutaneous REGEN-COV in preventing SARS-CoV-2 …

… of symptomatic SARS-CoV-2 infection (ie, COVID-19) during … for SARS-COV-2 anti-nucleocapsid
IgG antibodies during … Across all 7 study sites combined, the rate of REGEN-COV ISRs …

… and imdevimab in preventing progression to symptomatic SARS-CoV-2 infection among
asymptomatic, infected household contacts of infected individuals. The trial enrolled participants …

… of positive SARS-CoV-2 patients after receiving subcutaneous … of a monoclonal antibody
administration service during the … REGEN-COV, a monoclonal antibody combination of …

… A 1200 mg subcutaneous (SC) dose of REGEN-COV also … syndrome coronavirus 2 (SARS-CoV-2)
first emerged in 2019 … REGEN-COV in outpatients with asymptomatic SARS-CoV-2 …

… that subcutaneous injection of the neutralizing antibodies … Within the first week after
administration of REGEN-COV or … who developed a symptomatic SARS-CoV-2 infection. The …

… high-risk patients infected with SARS-CoV-2 within five days of … it was shown to reduce
symptomatic COVID-19 illness by 62… : a documented first positive SARS-CoV-2 polymerase-chain-…

… REGEN‐COV, a neutralizing antibody cocktail of casirivimab … symptomatic disease in
household contacts of infected … currently surging and highly infectious delta variant of Severe …

… of REGEN-COV against current variants of SARS-CoV-2. On 21 st … Subcutaneous
administration of the REGEN-COV ‘cocktail’ resulted in an 81% reduction in confirmed symptomatic …